A number of firms have modified their ratings and price targets on shares of Corium International (NASDAQ: CORI) recently: 9/4/2015 – Corium International was downgraded by analysts at Zacks from a “buy” rating to a “hold” rating. According to Zacks, “Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture […]
